Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Importance of minimal sentinel node tumor burden in melanoma staging

Alexander van Akkooi • 14 Sep 2024
ESMO 2024
Melanoma Skin Cancer

Alexander Van Akkooi, MD, PhD, Melanoma Institute Australia, Sydney, Australia, discusses the prognostic significance of minimal sentinel node (SN) tumor burden in melanoma, suggesting it be incorporated into the next American Joint Committee on Cancer (AJCC) staging system. Minimal SN tumor burden can differentiate between high-risk and low-risk stage 3A melanoma, guiding decisions regarding adjuvant treatment. This distinction could help identify patients who would benefit from adjuvant therapy while sparing low-risk patients from unnecessary treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alexander van Akkooi

Melanoma at ESMO 2025: SWOG S1801, NADINA, and more
1:13
Melanoma at ESMO 2025: SWOG S1801, NADINA, and more
Alexander van Akkooi • 18 Oct 2025
Primary analysis of Columbus-AD: encorafenib and binimetinib in high-risk stage II melanoma
1:43
Primary analysis of Columbus-AD: encorafenib and binimetinib in high-risk stage II melanoma
Alexander van Akkooi • 30 May 2025
The evolving role of surgery after neoadjuvant immunotherapy in melanoma
0:50
The evolving role of surgery after neoadjuvant immunotherapy in melanoma
Alexander van Akkooi • 15 Sep 2024
EORTC 1208 Minitub: a prospective registry of patients with SN positive melanoma
0:47
EORTC 1208 Minitub: a prospective registry of patients with SN positive melanoma
Alexander van Akkooi • 14 Sep 2024

Related Videos

Advances in TIL therapy for melanoma and solid tumors highlighted at ASCO 2026
3:13
Advances in TIL therapy for melanoma and solid tumors highlighted at ASCO 2026
Omid Hamid • 30 May 2026
ASCO 2026: personalized vaccines and triplet immunotherapy in melanoma
1:32
ASCO 2026: personalized vaccines and triplet immunotherapy in melanoma
Omid Hamid • 30 May 2026
Melanoma immunotherapy strategies shape treatment approaches across solid tumors
0:55
Melanoma immunotherapy strategies shape treatment approaches across solid tumors
Omid Hamid • 30 May 2026
Predictors of toxicity and tolerability with lifileucel in advanced melanoma
1:18
Predictors of toxicity and tolerability with lifileucel in advanced melanoma
Alexandra Haugh • 30 May 2026
The content of VJOncology is intended for healthcare professionals